About Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals Inc (ATNM) is a biopharmaceutical company focused on the development and commercialization of innovative targeted therapies for patients with cancers lacking effective treatment options. The company's lead product candidate is Iomab-B, a radioimmunotherapy consisting of the isotope actinium-225 linked to a monoclonal antibody. Iomab-B is currently being evaluated in a pivotal Phase 3 clinical trial as a conditioning regimen prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) who are over the age of 55. If approved, Iomab-B has the potential to become the standard of care for this patient population, as it has demonstrated promising results in previous clinical trials.

In addition to Iomab-B, Actinium Pharmaceuticals also has a pipeline of other product candidates targeting different types of cancers. These include Actimab-A, which is being evaluated in a Phase 2 trial for the treatment of patients with newly diagnosed AML who are unfit for standard chemotherapy, and Actimab-M, which is being developed for the treatment of patients with relapsed or refractory multiple myeloma. The company's innovative approach of combining targeted alpha particle therapy with monoclonal antibodies has the potential to provide more effective and safer treatment options for cancer patients.